Personalized Organ Engineering Platform OrganForge Enters Preclinical Trials: Growing Replacement Organs from Patient's Own Cells
eGenesis' OrganForge platform combines gene-edited pig organ decellularization scaffolds with patient autologous iPSC cell repopulation technology, successfully growing functional kidneys in primates, with preclinical trials now underway.
eGenesis announced on January 15, 2029, that its personalized organ engineering platform OrganForge has completed primate proof-of-concept and officially entered preclinical trial phase.
OrganForge's technical approach consists of three steps. First, CRISPR gene editing technology performs multiple genetic modifications on pig organs — knocking out glycan antigen genes that trigger immune rejection while introducing human immune regulation genes. Then, perfusion decellularization technology removes all cells from pig organs, preserving the extracellular matrix scaffold. Finally, the patient's own induced pluripotent stem cells (iPSCs) are differentiated into corresponding organ cells and repopulated onto the decellularized scaffold.
In 18-month primate trials, 5 rhesus macaques received OrganForge-grown kidney transplants. As of January 2029, all 5 monkeys survived with normal kidney function, with the longest survivor at 14 months.
eGenesis plans to submit an IND application to the FDA in the second half of 2029. If approved, OrganForge would become the first personalized xenogeneic organ engineering platform to enter human clinical trials. With approximately 120,000 people worldwide awaiting organ transplants, this technology could fundamentally solve the organ shortage crisis.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.